The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 26265498.
- Also identified by DOI 10.1093/cid/civ686.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
Medical subject headings
- Pneumococcal Infections
- Pneumococcal Vaccines